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Abstract 
Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement 
agencies world-wide, especially when there is limited direct head-to-head evidence for multiple 
technologies from randomised control trials (RCTs). Almost all NMAs include only data from RCTs. 
However, real-world evidence (RWE) is also becoming widely recognised as a source of clinical data. 
In this paper, we investigate methods for the inclusion of RWE and its impact on the level of 
uncertainty around the effectiveness estimates.  
Methods: We investigated the use of a range of methods for inclusion of RWE in evidence synthesis 
by applying them to an illustrative example in relapsing remitting multiple sclerosis (RRMS). We 
carried out a literature search to identify RCTs and RWE evaluating treatments in RRMS. To assess the 
impact of inclusion of RWE on the effectiveness estimates, we used Bayesian hierarchical and power 
prior models. We investigated the effect of the inclusion of RWE by varying the degree of down 
weighting of this part of evidence by the use of a power prior.  
Results: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding 
effect estimates for this example, this depended on the method of inclusion adopted for the RWE. The 
hierarchical models were effective in allowing for heterogeneity between study designs but this also 
further increased the level of uncertainty. 
Conclusion: The power prior method for the inclusion of RWE in NMAs indicates that the degree to 
which RWE is taken into account can have a significant impact on the overall level of uncertainty. The 
hierarchical modelling approach further allowed for accommodating differences between study types. 
Consequently further work investigating both empirical evidence for biases associated with individual 
RWE studies and methods of elicitation from experts on the extent of such biases is warranted. 
 
Introduction 
When evaluating new health technologies, traditionally data form randomised controlled trials (RCTs) 
have been considered a gold standard and, as such, used in meta-analysis in the evaluation process of 
new health technologies. More recently, there have been growing interest in the use of, so called, real 
world evidence (RWE), from observational studies, in health care evaluation. The inclusion of RWE is 
not a straightforward issue, as the effectiveness estimates obtained from RWE may be subject to bias, 
due to lack of randomisation, and hence use of randomised evidence may be preferable. However, 
data on effectiveness of new health technologies available from RCTs may be limited and 
observational studies, such as large cohort studies, can provide a substantial source of evidence, which 
makes the use of such data appealing.  Another reason for using RWE is to bridge a gap between 
efficacy and effectiveness to ensure that the evaluation process reflects what is expected in clinical 
practice in terms of effectiveness of new health technologies. Therefore recent methodological 
developments focus on appropriate methods of using such data. 
Network meta-analysis (NMA), which is designed to combine direct and indirect evidence from a 
number of studies investigating effectiveness of a number of treatments, has been used routinely in 
technology assessments conducted by many reimbursement agencies world-wide. It is a particularly 
useful meta-analytic tool when data from head-to-head trials on an intervention of interest are 
limited. NMA is then used to combine evidence from studies of heterogeneous treatment contrasts 
and is also known as mixed treatment comparisons meta-analysis. The aim of this paper is to 
investigate the use of NMA of data combining estimates obtained from both RCTs and RWE in a way 
that differentiates between the study designs to take into account of potential biases present in RWE. 
A number of methods have been used to combine evidence from different sources, which include 
naïve pooling (Li et al 1994), inclusion of external sources of evidence as prior information (Mak et al 
2009, Salpeter et al 2009) and hierarchical modelling (Provost at al 2000). These methods were 
originally introduced in standard pairwise meta-analysis and later generalised by Schmitz et al to 
mixed treatment comparison modelling (Schmitz et al 2013).  
In this paper, we discuss the use of a range of methods for combining RCT data with RWE in NMA 
setting. Methods considered are naïve pooling, hierarchical modelling and power transform prior 
approach (Ibrahim and Chen 2000). The methodology is applied to an illustrative example in relapsing-
remitting multiple sclerosis (RRMS). A systematic literature review was carried out to identify sources 
of data, from both RCTs and RWE, on the effectiveness of disease modifying therapies used in RRMS 
patients. Data were used to illustrate how the introduced methodology can be used to combine the 
data from the two types of sources of evidence and to compare the use of the alternative methods. 
 
Methods 
Illustrative Example and sources of evidence 
As our motivating example, we used disease modifying therapies used in patients with RRMS. We 
carried out a systematic review to identify studies, both randomised and observational, of such 
interventions with a main focus on effectiveness of fingolimod. To illustrate how the inclusion of RWE 
in the meta-analysis would impact on the estimates of effectiveness of fingolimod used in a technology 
appraisal, the literature search was limited to studies reported prior to January 2010, when fingolimod 
was given licencing authorisation. Data were extracted on the effect of each treatment on relapse 
rate. 
 
Network meta-analysis 
Random effects NMA model with adjustment for multi-arm trials (Ades et al 2007), was used as the 
base case meta-analytic model. To investigate the effect of fingolimod on relapse rates, the number 
of relapses 𝑟𝑖𝑘 in each study i and treatment arm k was modelled as count data following the Poisson 
distribution,  
 𝑟𝑖𝑘~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝛾𝑖𝑘𝐸𝑖𝑘) [1] 
where 𝐸𝑖𝑘 is the exposure time in person years and 𝛾𝑖𝑘  is the rate at which events (relapses) occur in 
arm k for study i. Following a standard generalized linear model approach, the conjugate log link was 
used with random true treatment effect differences 𝛿𝑖𝑏𝑘between treatments k and b which are 
assumed to follow common normal distribution. 
 log(𝛾𝑖𝑘) = 𝜇𝑖𝑏 + 𝛿𝑖𝑏𝑘𝐼𝑘≠𝑏 [2] 
 𝛿𝑖𝑏𝑘~𝑁(𝑑𝑏𝑘 , 𝜏
2). 
 
[3] 
Assuming consistency in the network (which means that, for example, average treatment effect 
difference 𝑑𝐴𝐶 , between treatments A and C, equals the sum of average treatment effect differences 
𝑑𝐴𝐵,between treatments A and B, and 𝑑𝐵𝐶,between treatments B and C) allows to represent each 
treatment effect contrast 𝑑𝑏𝑘 in the network as a difference of basic parameters which are average 
treatment effects of each treatment in the network compared to a common reference treatment 1; 
𝑑𝑏𝑘 = 𝑑1𝑘 − 𝑑1𝑏. Adopting a Bayesian approach to estimating the parameters of equations [1] – [3] 
requires that prior distributions are placed on the model parameters: the baseline study effects, 𝜇𝑖𝑏, 
for example, the uniform distribution 𝜇𝑖𝑏~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(−10,10), on the basic parameters, 
𝑑1𝑘~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(−10,10) and on the between-study variance 𝜏~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,2). 
For multi-arm studies, correlation between treatment effects relative to a common baseline 
treatment is taken into account, by assuming true treatment effects  𝛿𝑖(𝑏𝑘𝑛) follow common 
multivariate distribution which can be represented as series of univariate conditional distributions as 
follows 
 𝛿𝑖(𝑏𝑘1)~Normal(𝑑(𝑏𝑘1) ,   𝜎
2)    
𝛿𝑖(𝑏𝑘𝑛)| (
𝛿𝑖(𝑏𝑘1)
⋮
𝛿𝑖(𝑏𝑘𝑛−1)
) ~Normal (𝑑(𝑏𝑘𝑛) +
1
𝑛
∑(𝛿𝑖(𝑏𝑘𝑡) − 𝑑(𝑏𝑘𝑡))
𝑛−1
𝑡=1
,
(𝑛 + 1)
2𝑛
𝜎2) 
  
  
where n=2,…,p in the (p+1)-arm study of p treatment effect estimates relative to the reference 
treatment.  
Naïve pooling approach 
The above base case model is initially used to combine data from RCTs with RWE by including the 
observational studies at ‘face-value’. Data from all studies regardless of the study design were 
combined in the NMA described above.  
This model was then extended to account for the differences between the designs of the studies as 
described in the following sections. 
Power prior approach 
To take into account the differences in the study design between the RCTs and the observational 
studies, a ‘power transform prior’ approach (Ibrahim and Chen 2000) was adopted. This approach 
allows to down-weigh the RWE, thus making the data from this type of studies contribute less 
compared to data obtained from the RCTs. This is achieved by introducing a down-weighting factor, 
alpha (α), which varies between zero and one, with zero meaning that RWE is entirely discounted in 
the NMA, and with one indicating that all RWE is considered at ‘face-value’. The impact of different 
levels of weighting on the results of the NMA is performed by considering a series of values for alpha. 
The results are then summarised both in terms of the effect estimates (and their associated level of 
uncertainty) and the rankings that the treatments received (based on these effect estimates).  
Consider the annualised relapse rate ratio (ARRR) and assuming 𝛿 = log (𝐴𝑅𝑅𝑅), the overall joint 
posterior distribution is given by, 
 𝑃(𝛿|𝑅𝐶𝑇, 𝑂𝐵𝑆) 𝛼 𝐿(𝛿|𝑅𝐶𝑇) × 𝐿(𝛿|𝑂𝐵𝑆)𝛼𝑃(𝛿) [4] 
where 𝐿(𝜃|𝑌) is the likelihood of 𝜃 given data 𝑌, where data are split into the part obtained from RCTs 
and part from observational (OBS) studies to form separate likelihood contributions and then 
combined (with the weighting factor for OBS data) to give the overall posterior distribution. The RCT 
part of the data is modelled using a standard NMA random effects model, but the OBS portion of the 
data is included with a weight indexed by alpha. Assuming that the number of relapses follow a 
Poisson distribution, the OBS log likelihood (LL) in [1] becomes 
 
𝐿𝐿𝑖𝑘ℎ = 𝑙𝑜𝑔 (
𝛾𝑖𝑘ℎ
𝑟𝑖𝑘ℎ𝑒−𝛾𝑖𝑘ℎ
𝑟𝑖𝑘ℎ!
)
𝛼ℎ
 
[5] 
 𝐿𝐿𝑖𝑘ℎ = 𝛼ℎ(𝑟𝑖𝑘ℎ log(𝛾𝑖𝑘ℎ) − 𝛾𝑖𝑘ℎ − log (𝑟𝑖𝑘ℎ!)) [6] 
 
where h indexes the different values of 𝛼. 
 
Hierarchical model approach 
Another approach allowing to differentiate between study designs in network meta-analysis is 
introducing another level in a Bayesian hierarchical model of the NMA, modelling the between-studies 
heterogeneity of treatment effects within each  study design (RCT or RWE) and across study designs. 
Assuming j=1,2 where 1 represents the RCT data and 2 represents the RWE then equation [1] now 
becomes, 
 𝑟𝑖𝑘
𝑗 ~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝛾𝑖𝑘
𝑗 𝐸𝑖𝑘
𝑗 )  
 
And, similarly as in the general NMA model, using the log link function equation [2] becomes  
log(𝛾
𝑖𝑘
𝑗
) = µ𝑖𝑘
𝑗 + 𝛿𝑖𝑏𝑘
𝑗 𝐼𝑘≠𝑏  
  
 
The data from the two sources of evidence, the RCT data and RWE data, are modelled separately at 
the within-study and within-design level. Similarly as in (Schmitz et al 2013) assuming the RCT and 
RWE evidence are exchangeable, the study design estimates are combined to an overall measure of 
treatment effect using random effect. Thus, if 𝛿𝑖𝑏𝑘
1  and 𝛿𝑖𝑏𝑘
2  represent the treatment effect of 
treatment k against a reference treatment b, based on the RCT evidence and RWE respectively, then,  
 
 𝛿𝑖𝑏𝑘
1 ~𝑁(𝑑𝑏𝑘, 𝜎
2) [7] 
 𝛿𝑖𝑏𝑘
2 ~𝑁(𝑑𝑏𝑘, 𝜎
2) [8] 
 
where 𝑑𝑏𝑘 is the mean treatment effect of drug k compared to a reference treatment b and 𝜎
2 is the 
variance representing the design level between-studies heterogeneity. Prior distributions need to be 
placed on the parameters of the model, for example, the following “vague” prior distributions,  
𝑑𝑏𝑘~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(−10,10) 
𝜎~𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,2) 
This model was further extended by combining the power prior method described above with the 
hierarchal model in order to provide a further sensitivity analysis. This can be achieved by introducing 
a multiplicative factor to the variance for RWE, similarly as in the bias adjustment approach by Schmitz 
et al (2013). In our power prior approach this factor is related to the down-weighing factor α 
introduced by replacing 𝜎2 in [8] with 𝜎2/𝛼, where α takes values between 0 and 1. 
 
Implementation and model fit 
All models were implemented in WinBUGS version 1.4.3 (Lunn et al 2000). The first 10,000 simulations 
were discarded for all models as a burn-in. The main analyses were based on additional 20,000 
iterations in order to ensure convergence. Convergence was investigated by visually inspecting the 
trace and history plots. Model fit was evaluated using the total residual deviance and the DIC for each 
network size (Spiegelhalter et al 2002). Between-study heterogeneity was assessed using the standard 
deviation across random effects models. Inconsistency was assessed by assessing residual deviance 
and performing node splitting analysis (Dias et al 2010). 
 
Results 
Network structure 
Figure 1 illustrates the network diagram of direct comparisons between interventions in both the RWE 
and RCT data. The nodes represent individual interventions and the interconnecting lines and numbers 
represent the direct comparisons between interventions and the number of studies for each 
comparison in either the RCT or RWE. In total there were 23 studies included, 14 of them being RCTs. 
One may expect the RWE studies to have a larger sample size. However, in our example the average 
sample size in each arm for the RWE was 186, compared to the 288 in the RCT arms. The list of studies 
in NMA is included in the Appendix A. 
Figure 1: Network diagram including both RCTs and RWE studies up to the time of HTA submissions for 
fingolimod/Gilenya. The numbers represent how many direct evidence comparisons between treatments 
there are for the RCT/RWE with the node sizes being proportional to the number of subjects in each treatment 
arm and the thickness of the lines being proportional to the number of direct comparisons in the evidence 
base.  
 
Naive pooling using standard NMA 
Table 1 shows the annualised relapse rate ratios (and 95% credible intervals) for a NMA of RCTs (lower 
triangle) and a NMA of both sources of evidence with no adjustments for study design (upper triangle). 
As seen in table 1, the annualised relapse rate ratios (ARRRs) comparing all treatments vs placebo are 
less than one indicating a relative reduction in ARRs for all active treatments compared to placebo.  
When NMA treatment effect estimates are based on both sources of evidence, the levels of 
uncertainty can increase. For example, when comparing the effectiveness of fingolimod 0.5mg with 
Avonex the credible interval of the ARRR increased from (1.639 to 2.384), when using only RCT data, 
to (1.435 to 2.523), when combined data from both sources of evidence were used. This is likely due 
to the increased between-study heterogeneity, when the two different sources of evidence were 
combined. However, when the NMA estimated treatment effects using both sources of evidence 
(compared to only using the RCT data), 95% credible intervals were generally smaller than those 
associated with one single source of evidence (RTC data for the presented results). 
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 Table 1: Matrix table of annualised relapse rate ratios (95% credible intervals) for a NMA of RCTs only (bottom triangle), and from the NMA of both sources of evidence 
(upper triangle)  
 Placebo Natiluzimab Fingolimod 1.25 Fingolimod 0.5 Avonex Rebif 22 Rebif 44 Capaxone Betaferon 
Placebo  
0.405 0.459 0.415 0.784 0.768 0.752 0.603 0.703 
(0.293, 0.566) (0.352, 0.587) (0.317, 0.531) (0.650, 0.937) (0.614, 0.954) (0.602, 0.930) (0.497, 0.714) (0.579, 0.842) 
Natiluzimab 
0.315  1.163 1.052 1.987 1.945 1.902 1.528 1.780 
(0.257, 0.383) (0.738, 1.682) (0.665, 1.524) (1.344, 2.740) (1.301, 2.716) (1.280, 2.642) (1.020, 2.114) (1.198, 2.460) 
Fingolimod 1.25 
0.462 1.484  0.912 1.734 1.701 1.664 1.334 1.555 
(0.396, 0.536) (1.147, 1.893) (0.694, 1.174) (1.297, 2.274) (1.224, 2.318) (1.198, 2.264) (0.972, 1.765) (1.143, 2.067) 
Fingolimod 0.5 
0.422 1.355 0.916  1.919 1.882 1.841 1.476 1.720 
(0.360, 0.492) (1.043, 1.370) (0.766, 1.082) (1.435, 2.523) (1.353, 2.572) (1.327, 2.512) (1.075, 1.961) (1.265, 2.291) 
Avonex 
0.833 2.673 1.810 1.983  0.983 0.962 0.772 0.899 
(0.720, 0.957) (2.605, 3.375) (1.495, 2.164) (1.639, 2.384) (0.800, 1.204) (0.783, 1.176) (0.630, 0.926) (0.761, 1.052) 
Rebif 22 
0.723 2.321 1.573 1.723 0.872  0.985 0.791 0.921 
(0.601, 0.864) (1.753, 2.992) (1.242, 1.970) (1.351, 2.161) (0.698, 1.075) (0.780, 1.226) (0.619, 0.978) (0.742, 1.121) 
Rebif 44 
0.680 2.182 1.479 1.620 0.819 0.946  0.808 0.942 
(0.589, 0.781) (1.693, 2.753) (1.205, 1.798) (1.316, 1.971) (0.691, 0.963) (0.782, 1.138) (0.639, 0.991) (0.753, 1.154) 
Capaxone 
0.653 2.094 1.419 1.555 0.787 0.909 0.963  1.170 
(0.568, 0.750) (1.619, 2.650) (1.158, 1.728) (1.266, 1.901) (0.658, 0.939) (0.730, 1.122) (0.822, 1.126) (0.976, 1.408) 
Betaferon 
0.669 2.145 1.454 1.593 0.805 0.932 0.987 1.027  
(0.574, 0.770 (1.652, 2.712) (1.175, 1.771) (1.285, 1.955) (0.674, 0.947) (0.740, 1.155) (0.819, 1.171) (0.887, 1.173) 
 
Power prior 
The impact of application of the ‘power transform prior’ approach on the estimates of ARRRs (of each 
treatment compared to placebo) obtained from a NMA including both RCTs and RWE can be seen in 
Figure 2. The annualised rate ratios of each active treatment compared to placebo are shown for a 
range of values of the down-weighting factor (alpha) between zero (maximum down-weighting, i.e. 
RWE not included) and one (RWE considered at ‘face-value’). It can be seen that for most of the active 
treatments there is relatively little impact of assigning increasing weight to the RWE in terms of the 
point estimates for the ARRRs. However, the impact on uncertainty around these estimates was 
noticeable. For example, Figure 3 displays the estimates of the annualised relapse rate ratio along with 
the 95% credible intervals for fingolimod 0.5mg compared to placebo, for a range of values of the 
down-weighting factor (alpha). Whilst the point estimate remains fairly stable, the 95% Credible 
Interval widens as more weight is given to the RWE. This may seem counter-intuitive, as more 
evidence is being included in the analysis, and therefore uncertainty levels would be expected to 
decrease. However, in this random effects NMA, the between-studies heterogeneity can increase, 
which seems to be the case here which is supported by the level of discrepancies between RCTs and 
RWE studies seen in Table 1. This is represented by an increased between-studies variance (see table 
2) and in turn increased uncertainty in specific treatment effect estimates. However, due the fact that 
this happens for virtually all treatments (see Table 2) the net impact, in terms of treatment rankings, 
is minimal (see Figure 4). 
 
Figure 2: Annualised rate ratios of each active treatment compared to placebo for values of the down-
weighting factor (alpha) between zero (total down-weighting, i.e. RWE not included) and one (RWE 
considered at ‘face-value’).  
 
 
 
  
 
 
Figure 3: Annualised relapse rate ratio for fingolimod 1.25mg compared to placebo for values of the down-
weighting factor (alpha) between zero (total down-weighting, i.e. RWE not included) and one (RWE 
considered at ‘face-value’) together with lower and upper 95% Credible Interval limits. 
 
 
 
 
  
  
 
Table2: Annualised relapse rate ratios (and 95% credible intervals) of each active treatment compared to placebo for values of the down-weighting factor (alpha) between zero (total 
down-weighting, i.e. RWE not included) and one (RWE considered at ‘face-value’), along with the between study standard deviation (SD) for each corresponding alpha. 
 
Natiluzimab Fingolimod 
1.25mg 
Fingolimod 
0.5mg 
Avonex Rebif 22 Rebif 44 Capaxone Betaferon  
Alpha ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) ARRR (95% CI) Between 
study SD 
0.001 0.32 (0.26-0.39) 0.46 (0.4-0.54) 0.42 (0.36-0.5) 0.83 (0.72-0.95) 0.71 (0.6-0.86) 0.68 (0.59-0.78) 0.65 (0.57-0.75) 0.67 (0.58-0.77) 0.055 
0.1 0.32 (0.27-0.39) 0.46 (0.4-0.53) 0.42 (0.36-0.48) 0.79 (0.71-0.9) 0.73 (0.64-0.85) 0.69 (0.61-0.78) 0.66 (0.58-0.75) 0.68 (0.6-0.78) 0.045 
0.2 0.33 (0.27-0.41) 0.46 (0.39-0.53) 0.42 (0.36-0.5) 0.78 (0.7-0.88) 0.72 (0.62-0.84) 0.69 (0.61-0.79) 0.65 (0.57-0.73) 0.68 (0.61-0.77) 0.047 
0.3 0.33 (0.27-0.42) 0.45 (0.39-0.54) 0.42 (0.35-0.49) 0.77 (0.67-0.88) 0.73 (0.64-0.84) 0.7 (0.62-0.81) 0.65 (0.58-0.74) 0.69 (0.6-0.78) 0.057 
0.4 0.34 (0.27-0.43) 0.45 (0.38-0.54) 0.41 (0.35-0.5) 0.77 (0.68-0.89) 0.74 (0.63-0.87) 0.72 (0.62-0.84) 0.65 (0.56-0.74) 0.69 (0.61-0.8) 0.085 
0.5 0.35 (0.28-0.46) 0.46 (0.38-0.55) 0.42 (0.34-0.5) 0.78 (0.68-0.9) 0.75 (0.63-0.89) 0.72 (0.62-0.85) 0.64 (0.55-0.73) 0.7 (0.61-0.81) 0.1 
0.6 0.37 (0.29-0.5) 0.46 (0.37-0.57) 0.41 (0.33-0.51) 0.78 (0.67-0.92) 0.75 (0.62-0.91) 0.73 (0.61-0.88) 0.63 (0.53-0.73) 0.7 (0.59-0.82) 0.131 
0.7 0.38 (0.29-0.53) 0.46 (0.36-0.57) 0.42 (0.33-0.52) 0.78 (0.67-0.92) 0.75 (0.62-0.93) 0.73 (0.61-0.89) 0.62 (0.52-0.72) 0.7 (0.59-0.82) 0.144 
0.8 0.39 (0.29-0.54) 0.46 (0.36-0.58) 0.41 (0.32-0.53) 0.78 (0.66-0.93) 0.76 (0.62-0.94) 0.74 (0.61-0.91) 0.61 (0.51-0.72) 0.7 (0.58-0.83) 0.162 
0.9 0.4 (0.3-0.56) 0.46 (0.35-0.59) 0.41 (0.32-0.53) 0.78 (0.65-0.94) 0.76 (0.61-0.95) 0.74 (0.6-0.92) 0.61 (0.51-0.72) 0.7 (0.58-0.83) 0.173 
1 0.41 (0.3-0.57) 0.45 (0.35-0.59) 0.41 (0.32-0.53) 0.78 (0.65-0.93) 0.76 (0.61-0.95) 0.74 (0.6-0.93) 0.6 (0.49-0.71) 0.69 (0.57-0.83) 0.182 
 
 
Figure 4: Heatmap displaying rankings for each treatment (based on absolute annualised relapse rates 
estimated from NMA) for values of the down-weighting factor (alpha) between zero (total down-weighting, 
i.e. RWE not included) and one (RWE considered at ‘face-value’). 
 
 
 
Hierarchical model 
Table 3 shows the results of adopting a ‘power transform approach’ to down-weigh the RWE but this 
time using the hierarchical NMA with an additional level of hierarchy corresponding to the study 
design (presented results are for alpha = 1, results using a range of values of the factor alpha are 
included in Appendix B). Although the point estimates are in a broad agreement with the results 
presented above using a simpler ‘power transform approach’, it can be seen that the levels of 
uncertainty (in terms of the credible intervals) are generally greater. This is due to the fact that the 
hierarchical model explicitly takes into account the differences between study designs, thus allowing 
for additional variability across studies..  
 
 
 
AlphaRWE totally 
discounted
RWE @ 
facevalue
Treatment Rankings:
Green (highest) to red (lowest)
Table3: Annualised relapse rate ratios (95% credible intervals) for each active treatment compared to placebo 
using a hierarchical NMA to combine both RCTs and RWE studies and alpha=1. 
Treatment ARRR 95% Credible interval 
Natiluzimab 0.401 0.26 0.702 
Fingolimod 1.25mg 0.475 0.258 0.808 
Fingolimod 0.5mg 0.434 0.235 0.736 
Avonex 0.836 0.552 1.304 
Rebif 22 0.784 0.51 1.234 
Rebif 44 0.794 0.528 1.287 
Capaxone 0.629 0.404 0.958 
Betaferon 0.736 0.487 1.159 
 
 
Conclusion 
As previous research suggests, there are differences between RCTs and RWE studies (Ioannidis et al 
2001). However, the results did not show that including the RWE simply over or underestimated the 
treatment effect for each treatment, but rather that there was both over and underestimation for 
different treatments, supporting previous findings (Schmitz et al 2013). 
Both the hierarchical model and the hierarchical model with power transform prior are useful as they 
account for the heterogeneity between study designs. However, the results of these analyses did not 
differ significantly from the naïve pooling results or basic power transform prior results. They also 
produced wider credible intervals due to the adjustment for the between-studies design 
heterogeneity. Whilst the hierarchical models may be considered more appropriate (in that they take 
into account of the differences in sources of heterogeneity) care needs to be taken, and it is advised 
to compare the results with those from the naïve pooling in a sensitivity analysis to assess how results 
differ in practice. 
In our illustrative example the inclusion of RWE increased the overall level of uncertainty in the 
treatment effects, supporting pervious findings (Schmitz et al 2013). However, inclusion of RWE may 
increase the overall level of heterogeneity, and thus the uncertainty in estimated treatment effects – 
as was the case here. Thus, further evaluation of such methods in other settings, including the use of 
simulation studies, is warranted, and extension of the hierarchical modelling approach to allow for 
different types of RWE, either by inclusion of study-level covariates or by adding an extra level into 
the hierarchy, may ameliorate any potential increase in uncertainty regarding the treatment effects 
due to increased heterogeneity due to a broader evidence base.  
Implications for decision makers are that the methods can allow them to undertake assessments on a 
larger evidence base, and which includes a wider range of patient demographics and clinical 
characteristics. The implication for the pharmaceutical companies is that they will have a larger (and 
possibly a more representative) evidence/value dossier to submit to the various agencies (both 
regulators and HTA bodies). Implications for regulators and HTA bodies are that they will have to 
consider whether or not the RWE is sufficiently credible, whether this type of analysis is acceptable, 
and how the results should be interpreted and ultimately used. 
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 Appendix B.  
TableB.1: Annualised relapse rate ratios for each active treatment compared to placebo using a hierarchical 
NMA to combine both RCTs and RWE studies and a range of values of alpha. 
Rate ratios of every treatment against placebo for each power prior value in the hierachical 
model (N=natalizumab, F1.25=Fingolimod(1.25mg), F0.5=Fingolimod(0.5mg),A=Avonex, 
R2=Rebif 22, R44=Rebif 44, B=Betaferon and GA=Capaxone) 
Power N F1.25 F0.5 A R2 R4 GA B 
0.001 0.331 0.460 0.419 0.833 0.731 0.693 0.653 0.676 
0.1 0.343 0.459 0.424 0.827 0.739 0.703 0.641 0.678 
0.2 0.358 0.461 0.421 0.829 0.749 0.720 0.635 0.690 
0.3 0.357 0.463 0.421 0.820 0.750 0.728 0.632 0.688 
0.4 0.368 0.461 0.423 0.835 0.763 0.750 0.634 0.703 
0.5 0.380 0.460 0.418 0.830 0.763 0.758 0.630 0.708 
0.6 0.380 0.459 0.421 0.830 0.769 0.764 0.624 0.713 
0.7 0.381 0.459 0.423 0.819 0.766 0.762 0.619 0.705 
0.8 0.392 0.458 0.419 0.832 0.772 0.782 0.624 0.720 
0.9 0.400 0.463 0.424 0.831 0.778 0.788 0.619 0.725 
1 0.401 0.475 0.434 0.836 0.784 0.794 0.629 0.736 
  
 
